A major focus of the collaboration is the validation of CueFibrosis, InvitroCue’s patented image analysis application that automatically analyzes and quantifies fibrosis using histological whole-slide images. These algorithms have been developed in collaboration with renowned pathologists at the Massachusetts Institute of Technology and the Agency for Science, Technology and Research (A*STAR). Quantitative information of fibrosis progression and regression is essential for drug development. CueFibrosis provides such precise information while at the same time improving accuracy and throughput. The validation of CueFibrosis will be performed using tissue samples from HDB's animal models of various liver diseases.
“We are very pleased about this partnership with HDB that helps validate our patented CueFibrosis technology for the quantification of liver fibrosis. We see significant potential for the use of this technology in Asia and in extending this across other models.” said Dr. Steven Fang, Founder and Managing Director of InvitroCue.
“It’s exciting to enter this collaboration with InvitroCue to further validate CueFibrosis technology in application to preclinical drug research and development. We believe the implementation of this new technology platform would add extra value to our services on animal models, histopathology and biomarker. Our clients would benefit from more objective and quantitative analysis on the study results and obtain better understanding of the drug efficacy and mechanism of action.” commented Dr. Peiyuan Lin, Senior Vice President of HD Biosciences.
Besides CueFibrosis, the scope of this collaboration also includes the quantitative evaluation of tissue morphometry and biomarker expression using histological samples of other animal disease models from HDB, such as neuronal disease, lung disease and kidney disease. Both parties will benefit from working together to promote the technology application in drug research and development activities, and provide broader services to their clients.
InvitroCue provides innovative products and services in the fields of in vitro DMPK, in vitro toxicology and digital pathology utilising cell-based models and image analytics. InvitroCue's technologies have been developed and validated together with leading pharmaceutical companies and scientific collaborators, such as the Agency for Science, Technology and Research (A*STAR), National University of Singapore, Massachusetts Institute of Technology and renowned pathologists. The company employs these technologies and assays to support better decision making in preclinical studies, clinical trials and diagnostics. InvitroCue's solutions can be applied in the realms of drug testing as well as the research and development of cosmeceuticals and medical devices.
InvitroCue was established in 2012 as a spin-off from A*STAR and is based in Singapore.
InvitroCue Pte Ltd
81 Science Park Drive
#02-03 The Chadwick
Singapore Science Park 1
About HD Biosciences
HD Biosciences Co., Ltd. is a Shanghai-based, biology-focused preclinical drug discovery contract research organization (CRO). The company offers comprehensive service platforms around target validation, plate-based pharmacology, hit identification and lead discovery, therapeutic antibody discovery, in vivo pharmacology, as well as other research and development services. The company currently collaborates with eight of the world’s ten largest pharmaceutical companies and has established strategic partnership on many key R&D areas with the impacts to their portfolios. The strong scientific expertise, high quality and consistency in deliveries, constantly meet or exceed the expectations, have earned the company a great reputation in the industry and helped the company to build its widely recognised leadership in preclinical contract research services.
HD Biosciences Co., Ltd.
590 Ruiqing Road
Zhangjiang East Campus, Pudong,
Shanghai 201201, P.R.China
InvitroCue Pte Ltd
InvitroCue Pte Ltd